Corcept Loses Federal Circuit Patent Appeal Against Teva for Key Drug Korlym

summarizeSummary

Corcept Therapeutics announced that the U.S. Court of Appeals for the Federal Circuit ruled against it in a patent dispute with Teva Pharmaceuticals regarding its drug Korlym, affirming that Teva's generic version does not infringe two of Corcept's patents.

check_boxKey Events

• Federal Circuit Rules Against Corcept

  The U.S. Court of Appeals for the Federal Circuit found that Teva Pharmaceuticals' generic version of Korlym does not infringe two of Corcept's patents related to co-administering Korlym with CYP3A4 enzyme inhibitors.

• Affirms Prior District Court Verdict

  This ruling upholds a December 2023 verdict by the Federal District Court for the District of New Jersey, solidifying the legal outcome.

• Potential Impact on Korlym Exclusivity

  The decision weakens Corcept's patent protection for Korlym, its key commercialized drug, potentially paving the way for generic competition and impacting future revenues.

• Company Expresses Disappointment

  Corcept's CEO, Joseph K. Belanoff, expressed disappointment in the ruling and stated the company is considering options to pursue further judicial review.

auto_awesomeAnalysis

Corcept Therapeutics announced a significant legal setback as the U.S. Court of Appeals for the Federal Circuit affirmed a prior ruling that Teva Pharmaceuticals' generic version of Korlym does not infringe two of Corcept's patents. This decision, which upholds a December 2023 District Court verdict, weakens Corcept's intellectual property protection for Korlym, its first FDA-approved medication for endogenous hypercortisolism. The loss of patent exclusivity could lead to increased generic competition, potentially impacting Korlym's future sales and market share. The company expressed disappointment and stated it is considering further judicial review, indicating the battle for market exclusivity may continue.